Phase I/II Trial of Sorafenib (Nexavar) and RAD001 (Everolimus) in the Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 15 May 2014
At a glance
- Drugs Everolimus (Primary) ; Sorafenib
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 12 Jun 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 04 Jan 2012 Planned end date changed from 1 Jun 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 13 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.